Indications:
Octreotide inhibits growth hormone secretions and glucagon, secretion,useful in the treatment of acromegaly,Zollinger-ellison syndrome,secretory diarrhea,carcinoid syndrome and GI endocrine tumors.
Doses & Administrations:
Adult: subcutaneous Acromegaly: 50 - 100 mcg SC 2 - 3 times daily. Gastrinoma: 200 mcg SC 2 times daily. Pancreatic Tumors: 100 - 600 mcg/ day SC in 2 - 4 divided doses. Small bowl fistula: 225 - 300 mcg/day in 3 divided doses. Intravenous; Zollinger- ellison syndrome as continuous infusion 25 mcg/hour. Maintenance : 100 mcg SC Twice daily.
Contra Indications:
Hypersensitivity to the drug.
Precautions:
Diabetic patient,repeated injection should be avoided, pregnancy,lactation,renal impairement and gall bladder abnormalities.
Pregnancy Status:
Category "B"
Renal Failure Doses:
Dose adjustment may be necessary in patients with severe renal failure requiring dialysis since half life of drug can be increased. Ref:Micromeix
Lactation Status:
Unknown.
Interactions:
Cyclosporin.
Adverse Effects:
Diarrhea, loose stools,nausea,abdominal discomfort, headache,dizziness,fatigue,weakness,sinus bradycardia, arrythmias,pneumonia,cold symptoms,injection site pain, hyperglycemia,hypoglycemia and galactorrhea.
Nursing Considerations:
IV DILUTION-----0 to 200 mcg/ 50 ml (@ 15-30 min) 600 mcg/ 250 ml (@ 25 mcg/hr) 1250 mcg/ 250 ml (@ 50 mcg/hr) Usually 25 to 50 mcg/ hr. Dilute in NS preferably, but acn also dilute in D5W *(Ref:Vancouver Hospital Health Sciences Center, Parenteral Drug Therapy Manual)
Octreotide inhibits growth hormone secretions and glucagon, secretion,useful in the treatment of acromegaly,Zollinger-ellison syndrome,secretory diarrhea,carcinoid syndrome and GI endocrine tumors.
Doses & Administrations:
Adult: subcutaneous Acromegaly: 50 - 100 mcg SC 2 - 3 times daily. Gastrinoma: 200 mcg SC 2 times daily. Pancreatic Tumors: 100 - 600 mcg/ day SC in 2 - 4 divided doses. Small bowl fistula: 225 - 300 mcg/day in 3 divided doses. Intravenous; Zollinger- ellison syndrome as continuous infusion 25 mcg/hour. Maintenance : 100 mcg SC Twice daily.
Contra Indications:
Hypersensitivity to the drug.
Precautions:
Diabetic patient,repeated injection should be avoided, pregnancy,lactation,renal impairement and gall bladder abnormalities.
Pregnancy Status:
Category "B"
Renal Failure Doses:
Dose adjustment may be necessary in patients with severe renal failure requiring dialysis since half life of drug can be increased. Ref:Micromeix
Lactation Status:
Unknown.
Interactions:
Cyclosporin.
Adverse Effects:
Diarrhea, loose stools,nausea,abdominal discomfort, headache,dizziness,fatigue,weakness,sinus bradycardia, arrythmias,pneumonia,cold symptoms,injection site pain, hyperglycemia,hypoglycemia and galactorrhea.
Nursing Considerations:
IV DILUTION-----0 to 200 mcg/ 50 ml (@ 15-30 min) 600 mcg/ 250 ml (@ 25 mcg/hr) 1250 mcg/ 250 ml (@ 50 mcg/hr) Usually 25 to 50 mcg/ hr. Dilute in NS preferably, but acn also dilute in D5W *(Ref:Vancouver Hospital Health Sciences Center, Parenteral Drug Therapy Manual)
Unknown
Adverse Effects,
indication,
OCTREOTIDE ACETATE,
Precautions
